Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1735-1743

  Joulain, F ^a   Proskorovsky, I ^b   Allegra, C ^c   Tabernero, J ^d   Hoyle, M ^e   Iqbal, S U ^f   Van Cutsem, E ^g  

^a SANOFI   (France)

^b Modeling and Simulation   (Canada)

^c UNIVERSITY OF FLORIDA   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF EXETER   (United Kingdom)

^f SANOFI   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

aflibercept; mean survival; median survival; VELOUR

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885178607     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.523     Document Type: Article

References (26)

1. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27(11): 1829-1835.
2. Boag J (1948) The presentation and analysis of the result of radiotherapy. Br J Radiol 21(244): 189 passim.
3. Boag J (1949) Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc Ser B (Methodological) 11: 15-53.
4. Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI (2006) Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J 12(1): 37-47.
5. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE (2008) Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 107(1): 325-332.
6. Cleves M, Gould W, Gutierrez R, Marchenko Y (2002) An Introduction to Survival Analysis using Stata. Stata Press: College Station, TX.
7. Connock M, Hyde C, Moore D (2011) Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. Pharmacoeconomics 29(10): 827-837.
8. Davies A, Briggs A, Schneider J, Levy A, Ebeid O, Wagner S, Kotapati S, Ramsey S (2012) The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies. Health Outcomes Research in Medicine 3(1): e25-e36.
9. Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22(13): 1470-1479.
10. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson 3rd AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1): 38-50.
11. Hess GP, Wang PF, Quach D, Barber B, Zhao Z (2010) Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 6(6): 301-307.
12. Hind D, Tappenden P, Tumur I (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 12: 15.
13. Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G (2007) Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Invest 27(2): 85-93.
14. International Agency for Research on Cancer. WHO, Cancer Research UK (2011) CancerStats-Cancer Worldwide.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
16. Latimer N (2011) NICE DSU Technical Support. Undertaking survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Available at http://www.nicedsu.org.uk/ NICE%20DSU%20TSD%20Survival%20analysis-finalv2.pdf. Accessed on 25 June 2012.
17. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249(3): 420-425.
18. Muszbek N, Kreif N, Valderrama A, Agnes B, Ishak J, Ross P (2012) Modeling survival in hepatocellular carcinoma. Curr Med Res Opin 28(7): 1141-1153.
19. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M (2002) Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 11: 233-248.
20. Rosé M, Iqbal SU, Naoshy S, Mehta J, Chau I (2012) Current Treatment Patterns in First-Line (1L) and Second-Line (2L) Treatment for Metastatic Colorectal Cancer (mCRC) in Western Europe. Accepted and poster presented at ESMO World Congress GI June 2012.
21. Royston P (2001) The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerl 2: 89-104.
22. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26(35): 5721-5727.
23. Shilov GEe, Gurevich BL, Silverman RA (1977) Integral, Measure and Derivative: a Unified Approach, Richard A Silverman (edn). New York: Dover Publications: London: Constable.
24. Singer J, Willett J (2003) Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press: Oxford.
25. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2): 229-237.
26. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to folfiri improves survival in a phase iii randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28): 3499-3506.